Advertisement
ELV vs HUM
Which Stock Would AI Choose? Elevance Health (ELV) vs. Humana (HUM) Stock Comparison
Key Takeaways
- ELV delivered strong Q1 2026 results with adjusted EPS of $12.58, beating estimates and prompting a raised full-year outlook.
- HUM has posted year-to-date gains of about 15%, outperforming ELV's 1.6% amid Medicare payment optimism, though Q1 earnings loom on April 29.
- ELV commands a larger market cap of roughly $76 billion and a trailing P/E ratio (price-to-earnings) of 15, versus HUM's $26 billion cap and P/E of 22.
- Both stocks exhibit low betas around 0.5, signaling lower volatility relative to the market, but ELV shows superior profitability with a 2.6% profit margin compared to HUM's 0.9%.
- Analyst average price targets indicate potential upside, with ELV at $387 (10% above current levels) and HUM near $210 (flat to current).
Introduction
Elevance Health (ELV) and Humana (HUM) are prominent players in the U.S. managed healthcare sector, offering health insurance and benefits services amid evolving regulatory landscapes like Medicare Advantage adjustments. This stock comparison analyzes their recent market positioning, financial metrics, and performance drivers, aiding investors and traders assessing relative strength in healthcare. With sector headwinds from cost pressures and policy shifts, understanding contrasts in scale, profitability, and momentum helps inform portfolio decisions in a volatile environment.
ELV Overview and Recent Performance
Elevance Health, Inc. (ELV) is a leading health benefits provider offering commercial, Medicaid, and Medicare plans, with a diversified portfolio spanning pharmacy services and care delivery. In recent market activity, ELV shares have traded around $350, reflecting stability post-Q1 2026 earnings where operating revenue reached $49.5 billion (up 1.5% year-over-year) and adjusted EPS hit $12.58, exceeding forecasts. The company raised its full-year profit guidance, bolstered by operating discipline, AI integration for efficiency, and margin expansion in its exchange segment. Sentiment has improved on these beats and insider buying, though broader healthcare pressures linger. Year-to-date, shares are up modestly at 1.6%, with a 52-week range of $274–$428 underscoring resilience.
HUM Overview and Recent Performance
Humana Inc. (HUM) specializes in Medicare Advantage plans, government-sponsored programs, and primary care through its CenterWell brand. Recent weeks have seen HUM shares hover near $217, buoyed by favorable Medicare payment updates and partnerships like the Mark Cuban Cost Plus Drug collaboration. However, performance remains volatile, with year-to-date gains of 15% contrasting a 52-week range of $163–$315. Q4 2025 results showed an EPS beat at -$3.96 (less than expected loss) on $32.5 billion revenue, but profitability challenges persist with a negative operating margin. Investors await Q1 2026 earnings on April 29, amid Medicare Advantage scrutiny. Sentiment mixes optimism on cost innovations with caution over utilization trends.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto using machine learning strategies like signal agents and virtual portfolios with risk controls. These bots showcase impressive stats, including annualized returns ranging from +15% to +168%, win rates of 48%–88%, profit factors up to 11.7, and profit-to-drawdown ratios averaging around 6. Trading styles vary by timeframe (hours to months), sectors (e.g., semiconductors, industrials), and risk levels, with average drawdowns near $10,000. None currently focus on healthcare like ELV or HUM, emphasizing tech and energy. Explore these for automated insights tailored to market conditions.
Head-to-Head Comparison
Both ELV and HUM operate in managed care, but ELV offers broader exposure across commercial and government lines, while HUM leans heavily on Medicare Advantage, heightening regulatory risk. Growth drivers differ: ELV benefits from diversified revenue and recent margin gains (operating 5.3%), versus HUM's focus on care delivery amid utilization pressures (operating margin -1.8%).
Recent momentum favors ELV post-earnings stability and ROE of 12% (vs. HUM's 7%), though HUM edges YTD returns. Risk factors include similar debt/equity ratios (~73%) and Medicare policy shifts, but ELV's scale provides a buffer. Market sentiment tilts positive for ELV on analyst upgrades, while HUM trades at a premium valuation reflecting growth potential trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors ELV over HUM, driven by consistent earnings beats, superior profitability metrics like higher ROE and margins, and attractive valuation at a lower P/E amid stable trends. While HUM shows short-term momentum, ELV's scale and catalysts position it probabilistically stronger in the near term for relative performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELV is a Hold and HUM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELV’s FA Score shows that 1 FA rating(s) are green whileHUM’s FA Score has 3 green FA rating(s).
- ELV’s FA Score: 1 green, 4 red.
- HUM’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELV’s TA Score shows that 4 TA indicator(s) are bullish while HUM’s TA Score has 3 bullish TA indicator(s).
- ELV’s TA Score: 4 bullish, 5 bearish.
- HUM’s TA Score: 3 bullish, 5 bearish.
Price Growth
ELV (@Managed Health Care) experienced а -1.76% price change this week, while HUM (@Managed Health Care) price change was -5.14% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +0.72%. For the same industry, the average monthly price growth was +14.43%, and the average quarterly price growth was +37.57%.
Reported Earning Dates
ELV is expected to report earnings on Jul 22, 2026.
HUM is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Managed Health Care (+0.72% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
| ELV | HUM | ELV / HUM | |
| Capitalization | 85.7B | 43.3B | 198% |
| EBITDA | N/A | N/A | - |
| Gain YTD | 13.784 | 41.550 | 33% |
| P/E Ratio | 16.73 | 38.50 | 43% |
| Revenue | 200B | 137B | 146% |
| Total Cash | N/A | 22B | - |
| Total Debt | 31.8B | 14B | 227% |
ELV | HUM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 47 | 4 | |
P/E GROWTH RATING 1..100 | 37 | 8 | |
SEASONALITY SCORE 1..100 | 75 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ELV's Valuation (7) in the Managed Health Care industry is in the same range as HUM (11). This means that ELV’s stock grew similarly to HUM’s over the last 12 months.
ELV's Profit vs Risk Rating (91) in the Managed Health Care industry is in the same range as HUM (100). This means that ELV’s stock grew similarly to HUM’s over the last 12 months.
HUM's SMR Rating (95) in the Managed Health Care industry is in the same range as ELV (98). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
HUM's Price Growth Rating (4) in the Managed Health Care industry is somewhat better than the same rating for ELV (47). This means that HUM’s stock grew somewhat faster than ELV’s over the last 12 months.
HUM's P/E Growth Rating (8) in the Managed Health Care industry is in the same range as ELV (37). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
| ELV | HUM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 66% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 62% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 65% | N/A |
| MACD ODDS (%) | 2 days ago 63% | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 60% |
| Advances ODDS (%) | 16 days ago 56% | 9 days ago 60% |
| Declines ODDS (%) | 6 days ago 56% | 6 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 68% |
| Aroon ODDS (%) | 2 days ago 45% | 2 days ago 56% |
Advertisement
HUM and
Correlation & Price change
A.I.dvisor indicates that over the last year, HUM has been loosely correlated with UNH. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if HUM jumps, then UNH could also see price increases.